South Korea Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

South korea diabetes drugs market size in 2026 is estimated at USD 1.06 billion, growing from 2025 value of USD 995 million with 2031 projections showing USD 1.44 billion, growing at 6.34% CAGR over 2026-2031. This report is Segmented by Drug Class (Insulins, Oral Anti-Diabetics, Non-Insulin Injectable Drugs, Combination Drugs), Diabetes Type (Type-1 Diabetes and Type-2 Diabetes), Drug Origin (Innovator Brands and Biosimilars / Generics) Distribution Channel (Hospital Pharmacies, Retail / Community Pharmacies and Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

South Korea Diabetes Drugs Market Trends and Insights

Rising Diabetes Prevalence and Obesity Burden

Diabetes prevalence among adults aged 30 and older stood at 16.7% in 2024, making the disease Korea’s largest contributor to disability-adjusted life years. Obesity remains the key co-morbidity, as 73% of patients are overweight or obese. Sugar intake trends deepen the challenge, with one-fifth of children exceeding recommended levels. Combined, these factors keep demand for established oral agents high while encouraging adoption of GLP-1 and sodium-glucose cotransporter-2 (SGLT-2)-based therapies. Lean diabetes, affecting 8.8% of patients, adds clinical complexity and underpins the need for personalised regimens.

Preference for Innovative and Combination Therapies

Updated Korean Diabetes Association guidance directs clinicians toward multi-mechanism regimens that optimise glycaemic control, cardiovascular protection, and renal outcomes. Phase 3 data on a triple agonist (efpeglenatide) targeting GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors highlight the climate of clinically oriented innovation. Low-dose lobeglitazone studies demonstrate non-inferior efficacy with fewer side effects, supporting wider adoption.Market appetite for fixed-dose combinations is reinforced by the approval of the triple oral agent metformin-dapagliflozin-sitagliptin in 2025, offering simpler dosing and better adherence.

Stringent Price Cuts and Reimbursement Delays

Aggressive cost-containment under the Drug Expenditure Rationalization Plan compresses margins for novel therapies. Generic price indices declined only marginally from 4.79 to 3.40 versus the United States benchmark between 2020 and 2022, signifying limited relief. Manufacturers face protracted negotiations, prompting strategic launches of evidence packages that document cardio-renal benefits and long-term cost offsets.

Other drivers and restraints analyzed in the detailed report include:

• Ageing Population and Urban Lifestyles
• Government Reimbursement for Novel Agents
• Safety Concerns, Including Ketoacidosis

Segment Analysis

The South Korea diabetes drugs market size for oral agents stood at USD 467.2 million in 2025, accounting for 46.95% of total sales. SGLT-2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors dominate prescribing volumes, supported by an 87.5% medication adherence rate among older adults. Nevertheless, non-insulin injectables are accelerating at a double-digit 9.74% CAGR as GLP-1 receptor agonists prove effective in weight control and cardio-renal protection. Cardiovascular-outcome trials continue to expand label indications, encouraging earlier initiation in high-risk patients. Low-dose lobeglitazone achieved non-inferior glucose reduction while lowering side-effect rates, exemplifying the quest for safer profiles. Fixed-dose triple combinations reduce pill burden and improve adherence, supporting treatment intensification without patient fatigue.

Within non-insulin injectables, patient acceptance is rising due to thinner needles, autoinjector devices, and once-weekly dosing. Biosimilar development and local fill-and-finish capacity are expected to moderate prices and alleviate shortages over the next five years. Oral GLP-1 development programmes, leveraging permeability enhancers and nanoparticle carriers, could blur class boundaries by 2030. Insulin remains indispensable for Type 1 and advanced Type 2 patients, and high-concentration formulations provide flexibility for dose-intensive regimens aimed at overcoming insulin resistance.

In 2025, Type 2 patients generated 88.55% of the South Korea diabetes drugs market. Rising obesity and ageing lift the Type 2 case load, pushing forecasts toward 29.2% prevalence in men and 19.7% in women by 2030. Early combination therapy adoption aims to counter comorbidity clusters of hypertension and dyslipidaemia, improving overall outcomes. Type 1 population remains smaller yet technologically sophisticated, relying on sensor-integrated pumps and rapid-acting analogues for tight control. Paediatric Type 2 options are still limited to metformin, insulin, and liraglutide, indicating a clinical gap that innovators may address with youth-specific dosing and devices.

Lean diabetes, defined by lower body-mass index yet impaired insulin secretion, commands research attention for its unique pathophysiology. Herbal adjuncts, including red ginseng extract, demonstrated modest fasting glucose reductions in prediabetic adults, hinting at culturally familiar complementary options.

Complete Report Scope:

• By Drug Class
  • Insulins
  • Oral Anti-diabetic Drugs
  • Non-Insulin Injectables
  • Combination Drugs
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Drug Origin
  • Innovator Brands
  • Biosimilars / Generics
• By Distribution Channel
  • Hospital Pharmacies
  • Retail / Community Pharmacies
  • Online Pharmacies

List of Companies Covered in this Report:

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Merck
• Takeda Pharmaceuticals
• Boehringer Ingelheim
• AstraZeneca
• Janssen
• Pfizer
• Astellas Pharma
• Novartis
• Hanmi Pharmaceutical
• Chong Kun Dang
• GC Biopharma
• Samsung Bioepis
• LG Chem (LG Life Sciences)
• Dong-A ST
• Boryung Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support